BGB-21447-101: A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies {enrollment closed 12/22/25}

Objective

Closed Enrollment 12/22/25

Clinical Trial Details

Principal Investigator(s)

Andres Mendez-Hernandez, MD

Clinical Trial Categories

• Cancer
• Leukemia
• Lymphoma

Contact

Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org